New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
15:18 EDTRPRXRepros Therapeutics price target raised to $25 from $18 at Ladenburg
Ladenburg raised Repros price target following positive Phase III data from its pivotal trial of Androxal ZA-301. Shares are Buy rated.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
19:31 EDTRPRXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 1%. ALSO HIGHER: Repros Therapeutics (RPRX), up 21.9% after announcing acceptance for filing of NDA its enclomiphene citrate product... TCP International (TCPI), up 13.7% after announcing that product validation is proceeding as expected... Intrexon (XON), up 2.4% after signing a CRADA with NCI for RTS platform. DOWN AFTER EARNINGS: Sigma Designs (SIGM), down 2.8%... Micron Technology (MU), down 1.7%. ALSO LOWER: Conatus Pharmaceuticals (CNAT), down 4.4% after filing to sell common stock... TrueCar (TRUE), down 1.8% after being initiated with a Sell at B. Riley... ZIOPHARM Oncology (ZIOP), down 1.8% after filing to sell 11.72M shares of common stock for holders.
16:11 EDTRPRXRepros Therapeutics announces acceptance for filing of NDA
Subscribe for More Information
March 24, 2015
14:18 EDTRPRXRepros Therapeutics April volatility elevated at 144
Repros Therapeutics April call option implied volatility is at 144, May is at 108, August is at 107; compared to its 26-week average of 103 according to Track Data, suggesting large near term price movement

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use